CELL-FREE DNA HYDROXYMETHYLATION PROFILES IN THE EVALUATION OF PANCREATIC LESIONS

• Main Authors: KU CHIN-JEN, COLLIN FRANCOIS, LEVY SAMUEL, ARENSDORF PATRICK A
• Format: Patent
• Language: Chinese; English
• Published: 15.10.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

Disclosed herein are methods for identifying patients with pancreatic cancer and subjects at risk for developing pancreatic cancer, methods for monitoring a patient with an identified pancreatic lesion, methods for evaluating the effectiveness of a treatment used for a patient with pancreatic cancer, and methods for selecting a therapy for treating pancreatic cancer in a particular patient. The invention makes use of hydroxymethylation biomarkers, which in combination with one or more clinical parameters and optionally one or more additional types of biomarkers and/or patient-specific risk factors, exhibit a hydroxymethylation level that correlates with pancreatic cancer. Kits and other methods of use are also provided. 本文公开了用于鉴定患者患有胰腺癌以及鉴定受试者罹处于患胰腺癌风险中的方法、具有已鉴定胰腺病变的患者的监测方法、用于患胰腺癌患者的治疗效果的评估方法，以及用于治疗特定患者胰腺癌的疗法的选择方法。本发明利用羟甲基化生物标志物，其与一种或多种临床参数以及任选地一种或多种其它类型的生物标志物和/或患者特异性风险因子组合，表现出与胰腺癌相关的羟甲基化水平。还提供了试剂盒和其它使用方法。